Expression of CD44 variants and its association with survival in pancreatic cancer

Takuji Gotoda, Yasuhiro Matsumura, Hitoshi Kondo, Daizo Saitoh, Yasuhiro Shimada, Tomoo Kosuge, Yae Kanai, Tadao Kakizoe

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Since the CD44 variant 6(v6) molecule has been noted as a marker for tumor metastasis and prognosis in several tumors, we examined whether or not v6 is a useful marker for evaluating the prognosis of pancreatic cancer patients. In addition, we attempted to assess the clinicopathological implications for pancreatic cancer of the variant 2 (v2) isoform using a recently developed monoclonal antibody against a v2 epitope. The expression of CD44 variants was evaluated immunohistochemically in paraffin-embedded pancreatic cancer tissues from 42 patients who were confirmed surgically and histologically to have received curative resection. An indirect immunoperoxidase method was used with monoclonal antibodies against epitopes of the standard (CD44s) portion, v6 and v2. Protein expression data were evaluated statistically for any correlations with the length of survival or with histological parameters. The expression of CD44v6 and v2 was observed only in tumor cells, if at all. On the other hand, expression of total CD44 (including CD44v, as well as CD44s) was observed in both tumors and adjacent normal sites. Tumor tissue from 21 (50%) and 16 (38%) patients showed positive immunoreactivity with mAb 2F10 (anti-CD44v6) and mAb M23.6.1 (anti-CD44v2), respectively. The expression of CD44v6 and v2 was correlated with decreased overall survival (P = 0.0160 and P = 0.0125, respectively). A significant correlation was obtained between CD44v2 peptide expression and vessel invasion (P = 0.026). These results suggest that CD44v2 and CD44v6 may be useful markers for poor prognosis in curatively resected primary pancreatic cancer.

Original languageEnglish
Pages (from-to)1033-1040
Number of pages8
JournalJapanese Journal of Cancer Research
Volume89
Issue number10
Publication statusPublished - 1998 Oct
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Survival
Epitopes
Neoplasms
Monoclonal Antibodies
Tumor Biomarkers
Paraffin
Protein Isoforms
Neoplasm Metastasis
Peptides
Proteins

Keywords

  • CD44 variants
  • Immunohistochemistry
  • Metastasis
  • Pancreatic cancer
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gotoda, T., Matsumura, Y., Kondo, H., Saitoh, D., Shimada, Y., Kosuge, T., ... Kakizoe, T. (1998). Expression of CD44 variants and its association with survival in pancreatic cancer. Japanese Journal of Cancer Research, 89(10), 1033-1040.

Expression of CD44 variants and its association with survival in pancreatic cancer. / Gotoda, Takuji; Matsumura, Yasuhiro; Kondo, Hitoshi; Saitoh, Daizo; Shimada, Yasuhiro; Kosuge, Tomoo; Kanai, Yae; Kakizoe, Tadao.

In: Japanese Journal of Cancer Research, Vol. 89, No. 10, 10.1998, p. 1033-1040.

Research output: Contribution to journalArticle

Gotoda, T, Matsumura, Y, Kondo, H, Saitoh, D, Shimada, Y, Kosuge, T, Kanai, Y & Kakizoe, T 1998, 'Expression of CD44 variants and its association with survival in pancreatic cancer', Japanese Journal of Cancer Research, vol. 89, no. 10, pp. 1033-1040.
Gotoda T, Matsumura Y, Kondo H, Saitoh D, Shimada Y, Kosuge T et al. Expression of CD44 variants and its association with survival in pancreatic cancer. Japanese Journal of Cancer Research. 1998 Oct;89(10):1033-1040.
Gotoda, Takuji ; Matsumura, Yasuhiro ; Kondo, Hitoshi ; Saitoh, Daizo ; Shimada, Yasuhiro ; Kosuge, Tomoo ; Kanai, Yae ; Kakizoe, Tadao. / Expression of CD44 variants and its association with survival in pancreatic cancer. In: Japanese Journal of Cancer Research. 1998 ; Vol. 89, No. 10. pp. 1033-1040.
@article{07dee2af32094dd2918353b3c98611e4,
title = "Expression of CD44 variants and its association with survival in pancreatic cancer",
abstract = "Since the CD44 variant 6(v6) molecule has been noted as a marker for tumor metastasis and prognosis in several tumors, we examined whether or not v6 is a useful marker for evaluating the prognosis of pancreatic cancer patients. In addition, we attempted to assess the clinicopathological implications for pancreatic cancer of the variant 2 (v2) isoform using a recently developed monoclonal antibody against a v2 epitope. The expression of CD44 variants was evaluated immunohistochemically in paraffin-embedded pancreatic cancer tissues from 42 patients who were confirmed surgically and histologically to have received curative resection. An indirect immunoperoxidase method was used with monoclonal antibodies against epitopes of the standard (CD44s) portion, v6 and v2. Protein expression data were evaluated statistically for any correlations with the length of survival or with histological parameters. The expression of CD44v6 and v2 was observed only in tumor cells, if at all. On the other hand, expression of total CD44 (including CD44v, as well as CD44s) was observed in both tumors and adjacent normal sites. Tumor tissue from 21 (50{\%}) and 16 (38{\%}) patients showed positive immunoreactivity with mAb 2F10 (anti-CD44v6) and mAb M23.6.1 (anti-CD44v2), respectively. The expression of CD44v6 and v2 was correlated with decreased overall survival (P = 0.0160 and P = 0.0125, respectively). A significant correlation was obtained between CD44v2 peptide expression and vessel invasion (P = 0.026). These results suggest that CD44v2 and CD44v6 may be useful markers for poor prognosis in curatively resected primary pancreatic cancer.",
keywords = "CD44 variants, Immunohistochemistry, Metastasis, Pancreatic cancer, Prognosis",
author = "Takuji Gotoda and Yasuhiro Matsumura and Hitoshi Kondo and Daizo Saitoh and Yasuhiro Shimada and Tomoo Kosuge and Yae Kanai and Tadao Kakizoe",
year = "1998",
month = "10",
language = "English",
volume = "89",
pages = "1033--1040",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Expression of CD44 variants and its association with survival in pancreatic cancer

AU - Gotoda, Takuji

AU - Matsumura, Yasuhiro

AU - Kondo, Hitoshi

AU - Saitoh, Daizo

AU - Shimada, Yasuhiro

AU - Kosuge, Tomoo

AU - Kanai, Yae

AU - Kakizoe, Tadao

PY - 1998/10

Y1 - 1998/10

N2 - Since the CD44 variant 6(v6) molecule has been noted as a marker for tumor metastasis and prognosis in several tumors, we examined whether or not v6 is a useful marker for evaluating the prognosis of pancreatic cancer patients. In addition, we attempted to assess the clinicopathological implications for pancreatic cancer of the variant 2 (v2) isoform using a recently developed monoclonal antibody against a v2 epitope. The expression of CD44 variants was evaluated immunohistochemically in paraffin-embedded pancreatic cancer tissues from 42 patients who were confirmed surgically and histologically to have received curative resection. An indirect immunoperoxidase method was used with monoclonal antibodies against epitopes of the standard (CD44s) portion, v6 and v2. Protein expression data were evaluated statistically for any correlations with the length of survival or with histological parameters. The expression of CD44v6 and v2 was observed only in tumor cells, if at all. On the other hand, expression of total CD44 (including CD44v, as well as CD44s) was observed in both tumors and adjacent normal sites. Tumor tissue from 21 (50%) and 16 (38%) patients showed positive immunoreactivity with mAb 2F10 (anti-CD44v6) and mAb M23.6.1 (anti-CD44v2), respectively. The expression of CD44v6 and v2 was correlated with decreased overall survival (P = 0.0160 and P = 0.0125, respectively). A significant correlation was obtained between CD44v2 peptide expression and vessel invasion (P = 0.026). These results suggest that CD44v2 and CD44v6 may be useful markers for poor prognosis in curatively resected primary pancreatic cancer.

AB - Since the CD44 variant 6(v6) molecule has been noted as a marker for tumor metastasis and prognosis in several tumors, we examined whether or not v6 is a useful marker for evaluating the prognosis of pancreatic cancer patients. In addition, we attempted to assess the clinicopathological implications for pancreatic cancer of the variant 2 (v2) isoform using a recently developed monoclonal antibody against a v2 epitope. The expression of CD44 variants was evaluated immunohistochemically in paraffin-embedded pancreatic cancer tissues from 42 patients who were confirmed surgically and histologically to have received curative resection. An indirect immunoperoxidase method was used with monoclonal antibodies against epitopes of the standard (CD44s) portion, v6 and v2. Protein expression data were evaluated statistically for any correlations with the length of survival or with histological parameters. The expression of CD44v6 and v2 was observed only in tumor cells, if at all. On the other hand, expression of total CD44 (including CD44v, as well as CD44s) was observed in both tumors and adjacent normal sites. Tumor tissue from 21 (50%) and 16 (38%) patients showed positive immunoreactivity with mAb 2F10 (anti-CD44v6) and mAb M23.6.1 (anti-CD44v2), respectively. The expression of CD44v6 and v2 was correlated with decreased overall survival (P = 0.0160 and P = 0.0125, respectively). A significant correlation was obtained between CD44v2 peptide expression and vessel invasion (P = 0.026). These results suggest that CD44v2 and CD44v6 may be useful markers for poor prognosis in curatively resected primary pancreatic cancer.

KW - CD44 variants

KW - Immunohistochemistry

KW - Metastasis

KW - Pancreatic cancer

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=0031757253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031757253&partnerID=8YFLogxK

M3 - Article

C2 - 9849582

AN - SCOPUS:0031757253

VL - 89

SP - 1033

EP - 1040

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 10

ER -